Explore the preclinical development of 9MW2821, a next-generation antibody-drug conjugate targeting Nectin-4-expressing cancers with precision and efficacy.
Exploring how trisulfide bonds impact antibody-drug conjugates and cancer therapy effectiveness through molecular modifications.